Thailand Approves New Oral Antibiotic Nuzolvence for Gonorrhoea Treatment
Thailand's Food and Drug Administration has approved Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea. Dr. Reddy's Laboratories, with support from The GARDP Foundation, led the priority review submission for this drug. Thailand is the second country to approve this new chemical entity, following the U.S. Food and Drug Administration's approval six months prior. This approval marks a significant step in combating gonorrhoea, especially given the rising concerns about antibiotic resistance.
Key Points
- Thailand's FDA approved Nuzolvence (zoliflodacin) for uncomplicated urogenital gonorrhoea.
- Nuzolvence is a first-in-class oral antibiotic.
- Dr. Reddy's Laboratories, supported by The GARDP Foundation, led the review submission.
- Thailand is the second country to approve the drug, after the U.S. FDA approved it six months earlier.
Exam Facts
- Thailand's Food and Drug Administration (FDA) approved Nuzolvence (zoliflodacin).
- Dr. Reddy's Laboratories led the priority review submission.
- The GARDP Foundation supported the submission.
- The U.S. FDA approved the drug six months prior.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.